Interferons News and Research

RSS

Interferon beta not associated with less progression of disability in patients with RRMS

Among patients with relapsing-remitting multiple sclerosis (MS), treatment with the widely-prescribed drug to treat MS, interferon beta, was not associated with less progression of disability, according to a study in the July 18 issue of JAMA.

18 Jul 2012

Commensal bacteria essential to fight off viral infections

Healthy humans harbor an enormous and diverse group of bacteria and other bugs that live within their intestines. These microbial partners provide beneficial aid in multiple ways - from helping digest food to the development of a healthy immune system.

19 Jun 2012

New insights into how body's innate immunity is triggered to create effective immune response

Singapore scientists from Bioprocessing Technology Institute (BTI) under the Agency of Science, Technology and Research (A*STAR) have for the first time, identified the molecular 'switch' that directly triggers the body's first line of defence against pathogens, more accurately known as the body's "innate immunity".

11 May 2012

Researchers uncover mechanism that explains link between autoimmunity and atherosclerosis

Patients with autoimmune diseases often show a predisposition to develop "hardening of the arteries" or atherosclerosis. LMU researchers have now uncovered a mechanism that establishes a causal link between the two disorders.

5 Apr 2012

New method uses E. coli bacteria to engineer human therapeutic glycoproteins

Escherichia coli - a bacteria considered the food safety bane of restaurateurs, grocers and consumers - is a friend. Cornell University biomolecular engineers have learned to use E. coli to produce sugar-modified proteins for making pharmaceuticals cheaper and faster.

27 Mar 2012

Gilenya - pill for relapsing-remitting multiple sclerosis recommended by NICE

The National Institute for Health and Clinical Excellence (Nice) issued new draft guidance recommending fingolimod (brand name Gilenya) on the NHS for some patients with a form of MS. The new drug can help reduce the number of relapses in adults with highly active relapsing-remitting multiple sclerosis (RRMS), which is characterized by periods when symptoms worsen and then improve.

19 Mar 2012

Study investigates how cytokine IFN-λ release is regulated

In new research appearing in this month's issue of the journal Nature Immunology, Roy Curtiss, director of the Center for Infectious Diseases and Vaccinology at the Biodesign Institute at Arizona State University, along with international collaborators, investigates the coordination of a particular type of immune response, involving the release of of IFN-λ- a cell-signaling protein molecule known as a cytokine.

10 Feb 2012

Scientists identify genetic mutation that causes rare childhood disease

An international collaboration of scientists, including researchers at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the National Institutes of Health, has identified a genetic mutation that causes a rare childhood disease characterized predominantly by inflammation and fat loss.

1 Nov 2011

COPAXONE reduces loss of brain volume in patients with RRMS

Results from a five-year study of treatment-naïve patients with relapsing-remitting multiple sclerosis (RRMS) demonstrated that patients treated with COPAXONE (glatiramer acetate injection) showed significant reduced loss of brain volume compared to patients treated with other disease modifying therapies.

12 Oct 2011

PROLOR receives U.S. patent allowance for CTP-modified interferons

PROLOR Biotech, Inc. today announced that it received a notice of allowance from the U.S. Patent and Trademark Office (PTO) for a patent application covering PROLOR's CTP-modified interferons.

12 Oct 2011

Researchers modify HIV in a way that makes it no longer able to suppress immune system

Researchers at Johns Hopkins have modified HIV in a way that makes it no longer able to suppress the immune system. Their work, they say in a report published online September 19 in the journal Blood, could remove a major hurdle in HIV vaccine development and lead to new treatments.

27 Sep 2011

CEL-SCI receives Chinese patent for Multikine cancer drug

CEL-SCI Corporation today announced that the Chinese patent office has issued a key patent covering CEL-SCI's investigational cancer drug, Multikine.

18 Aug 2011

High cost of multiple sclerosis drugs

According to a study released this Wednesday, drugs used in the hope of slowing multiple sclerosis progression may help some patients, but at a very high cost.

21 Jul 2011

Scientists discover molecular mechanism that could help develop new MS treatments

Scientists at The University of Nottingham have discovered a molecular mechanism which could bring about the development of new treatments for Multiple Sclerosis (MS) — a chronic inflammatory disease of the central nervous system.

22 Jun 2011

New avenue for treating breast cancer

Researchers at the CHUM Research Centre and the Peter MacCallum Cancer Centre in Australia have identified a new avenue for treating breast cancer.

17 May 2011

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

The Australian Therapeutic Goods Administration (TGA) has granted approval for FAMPYRA, (fampridine) 10 mg Modified Release (MR) tablet, for the symptomatic improvement of walking ability in adult patients with multiple sclerosis (MS) who have shown improvement after eight weeks of treatment.

16 May 2011

Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

Idera Pharmaceuticals, Inc. announced today the presentation of data from a four-week Phase 1 clinical trial of IMO-2125 in combination with ribavirin in treatment-naïve patients chronically infected with hepatitis C virus genotype 1.

2 Apr 2011

Strong 'innate immunity' effective in chikungunya patients

Chikungunya is transmitted by mosquitoes of the genus Aedes. The disease is spreading in the world and periodically sparks new outbreaks. Africa, Asia, the Indian Ocean and even Southern Europe are now affected.

23 Mar 2011

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

3 Mar 2011

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

German researchers have found a significant association of IL28B genotypes to interferon-based antiviral treatment outcome, and to graft inflammation caused by hepatitis C virus (HCV). The study determined that the presence of G-allele serves as a marker for severe HCV-induced graft inflammation, as well as a predictor for unsuccessful treatment. Study findings—the largest to report on the role IL28B variants in a transplant cohort with recurrent HCV—are published in the March issue of Liver Transplantation, a journal of the American Association for the Study of Liver Diseases.

2 Mar 2011

Interferons News and Research

Interferon beta not associated with less progression of disability in patients with RRMS

Commensal bacteria essential to fight off viral infections

New insights into how body's innate immunity is triggered to create effective immune response

Researchers uncover mechanism that explains link between autoimmunity and atherosclerosis

New method uses E. coli bacteria to engineer human therapeutic glycoproteins

Gilenya - pill for relapsing-remitting multiple sclerosis recommended by NICE

Study investigates how cytokine IFN-λ release is regulated

Scientists identify genetic mutation that causes rare childhood disease

COPAXONE reduces loss of brain volume in patients with RRMS

PROLOR receives U.S. patent allowance for CTP-modified interferons

Researchers modify HIV in a way that makes it no longer able to suppress immune system

CEL-SCI receives Chinese patent for Multikine cancer drug

High cost of multiple sclerosis drugs

Scientists discover molecular mechanism that could help develop new MS treatments

New avenue for treating breast cancer

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

Strong 'innate immunity' effective in chikungunya patients

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News